Long-Lasting painkiller may cut opioid use after nose jobs

NCT ID NCT07689162

First seen Jul 08, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This trial tests whether a long-acting form of the painkiller bupivacaine (liposomal bupivacaine) works better than the standard version for controlling pain after rhinoplasty (nose surgery). Adults undergoing open rhinoplasty for any reason—medical or cosmetic—will receive one of the two drugs during surgery. Researchers will measure total opioid use and pain levels over the first three days to see which approach leads to less discomfort and fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Liposomal bupivacaine (Exparel) and standard bupivacaine (Marcaine)
What this could lead to
If liposomal bupivacaine works better, it could reduce opioid use and improve recovery after rhinoplasty.
What could go wrong
This is a small Phase 2 trial, so results may not apply broadly. Liposomal bupivacaine is more expensive and may not prove superior.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAIN, POSTOPERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.